Determinants of Delay in Diagnosis and Treatment in Multi Drug-Resistant Tuberculosis Patients in Health Facilities

Yusup Subagio Sutanto, Paulus Wisnu Kuncoro Murti, Reviono Reviono, Ari Natalia Probandari, Hendra Kurniawan


Background: Multidrug-resistant tubercu­lo­sis (MDR-TB) is a serious threat to global TB control programs. According to WHO, there are 23,000 cases of TB multidrug-/rifampicin-resistant (MDR/RR-TB) in Indonesia. In 2017, there were 442,000 of TB cases. There were 8,600 - 15,000 MDR/RR-TB cases, of which 2.4% were new cases and 13% were previously treated TB cases. This study aims to determine the factors that influence the delay in diagnosis and treatment of MDR-TB patients.

Subjects and Method: This study was a cross-sectional study conducted at Dr. Moe­wardi hospital, from Sep­tem­ber to October 2017, Surakarta, Central Java. A sample of 73 MDR-TB patients with disabilities on medical records was selected for this study. The depen­dent variables were delay in diagnosis and delay in therapy of MDR-TB cases. The inde­pendent variables were age, gender, distance to health facilities, and type of health facilities. Data were collected from medical records of MDR-TB patients who were treated from March 2012 to March 2017. Data were analyzed using the chi-square model.

Results: Median delay in diagnosis = 4 days. Median treatment delay = 12 days. The average patient who had delayed MDR-TB therapy (≥4 days) was 44 years old (Mean= 44.19; SD= 12.64). Delay in MDR-TB diagnosis was not significantly associated with gender (OR= 0.53; 95% CI= 0.18 to 1.57; p= 0.264), distance to health facility (OR= 1.56; 95% CI= 0.58 to 4.21; p= 0.389), and type of health facility (OR= 0.60; 95% CI= 0.26 to 1.41; p= 0.983). The average of patient who had delayed MDR-TB therapy (≥12 days) was 41 years old (Mean= 41.39; SD= 12.69). Treatment delay was not significantly related to gender (OR= 0.45; 95% CI= 0.16 to 1.26; p= 0.137), distance to health facility (OR=1.44; 95% CI= 0.55 to 3.78; p= 0.466), and type of health facility (OR= 2.31; 95% CI= 1.03 to 5.21; p= 2.967).

Conclusion: There was no statistically sig­nificant relationship between gender, dis­tance from the patient's home to health facilities, and type of health facility with the delay in diag­nosis and treatment of MDR-TB patients.

Keywords: diagnosis, treatment, TB-MDR

Correspondence: Yusup Subagio Sutanto. Department of Pulmo­nology and Respiratory Medicine, Faculty of Medicine Universitas Sebelas Maret/ Dr. Moe­wardi Hospital, Surakarta. Jl. Kolonel Sutarto No.132, Jebres, Surakarta, Central Java 57126. Email: Mobile: 0811284165.

Indonesian Journal of Medicine (2021), 06(01): 14-22


Full Text:



Adenager GS, Alemseged F, Asefa H, Gebremedhin AT (2017). Factors asso-ciated with treatment delay among pulmonary tuberculosis patients in public and private health facilities in Addis Ababa, Ethiopia. Tuberc Res Treat. 1-9. doi: 10.1155/2017/5120841.

Alavi SM, Bakhtiyariniya P, Albagi A (2015). Factors associated with delay in diagnosis and treatment of pulmonary tuberculosis. Jundishapur J Microbiol. 8(3): 8-11. doi: 10.5812/jjm.19238.

Bekana W, Sisay M, Baye Y (2017). Evaluation of factors affecting patient delay in the diagnosis and treatment of tb among tb patients attending in Hiwot Fana specialized University Hospital, Harar, Eastern Ethiopia. J Infect Dis Preve Med. 05(01): 1-7. doi: 10.4172/-2329-8731.1000149.

Farazi A, Jabbariasl M (2012). Time delay and associated factors in diagnosis and treatment of pulmonary tuberculosis in Markazi Province. J Health Res. 1(1): 46-53.

Kemenkes RI (2013). Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuberkulosis (National Guidelines for Tuberculosis Medical Service Admi-nistration). Jakarta: Kementerian Ke-sehatan Republik Indonesia.

Kemenkes RI (2011). Pedoman nasional pengendalian tuberkulosis-keputusan Menteri Kesehatan Republik Indo-nesia (National guidelines for tuberculosis control-decree of the Minister of Health of the Republic of Indo-nesia). Jakarta: Kementerian Kesehatan Republik Indonesia.

Kemenkes RI (2014). Petunjuk teknis ma-najemen terpadu pengendalian resistan obat (Technical guidelines for integrated management of drug resistance management). Jakarta: Kementerian Kesehatan Republik Indonesia.

Konda S, Melo C, Giri P, Behera A (2014). Determinants of delays in diagnosis and treatment of pulmonary tuberculosis in a new urban township in India: A cross-sectional study. Int J Med Sci Public Health. 3(2): 140. doi: 10.5455/ijmsph.2013.011120131.

Menteri Kesehatan Republik Indonesia (2014). Pedoman Nasional Tuberku-losis (National Tuberculosis Guide-lines). Jakarta: Kementerian Kese-hatan Republik Indonesia.

Nyatichi FO, Amimo FA (2016). Factors contributing to delay in seeking treatment among pulmonary tuberculosis patients in Suneka Sub-County, Kenya. J Health Educ. Res. Dev. 4(2). doi: 10.4172/2380-5439.1000170.

Osei E, Akweongo P, Binka F (2015). Factors associated with delay in diagnosis among tuberculosis patients in Hohoe Municipality, Ghana. BMC Public Health. 15(1): 1-11. doi: 10.1186/s128-89-015-1922-z.

Rifat M, Hall J, Oldmeadow C, Husain A, Milton AH (2015). Health system delay in treatment of multidrug resistant tuberculosis patients in Bangladesh. BMC Infect Dis, 15(1): 1-8. doi: 10.1186/s12879-015-1253-9.

Said K, Hella J, Mhalu G, Chiryankubi M, Masika E, Maroa T, Mhimbira F, et al. (2017). Diagnostic delay and associa-ted factors among patients with pul-monary tuberculosis in Dar es Salaam, Tanzania. Infect Dis Poverty. 6(1): 1-10. doi: 10.1186/s40249-017-0276-4.

Lusignani LS, Quaglio G, Atzori A, Nsuka J, Grianger R, Palma MDC, Putoto G, et al. (2013). Factors associated with patient and health care system delay in diagnosis for tuberculosis in the province of Luanda, Angola. BMC Infect Dis. 13(1). doi: 10.1186/1471-2334-13-168.

WHO (2016). WHO treatment guidelines for drug resistant tuberculosis. Gene-va: WHO Document Production Services.

Zhang X, Yin J, Li H, Li S, Walley J, Zou G, Zhang Z, et al. (2015). Diagnostic and treatment delays of multidrug-resist-ant tuberculosis before initiating treatment: a cross-sectional study. Trop Med Int Health. 20(11): 1431-1437. doi: 10.1111/tmi.12566.


  • There are currently no refbacks.